Grifols, S.A. (NASDAQ:GRFS - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $7.76 and traded as high as $9.87. Grifols shares last traded at $9.72, with a volume of 822,088 shares changing hands.
Wall Street Analysts Forecast Growth
GRFS has been the topic of a number of recent research reports. JPMorgan Chase & Co. boosted their price objective on Grifols from $7.60 to $10.30 and gave the stock a "neutral" rating in a research note on Tuesday, June 17th. Wall Street Zen raised shares of Grifols from a "buy" rating to a "strong-buy" rating in a research report on Monday, July 7th.
Get Our Latest Stock Analysis on Grifols
Grifols Stock Down 0.6%
The firm has a 50-day moving average of $8.67 and a two-hundred day moving average of $7.82. The company has a market capitalization of $6.87 billion, a PE ratio of 8.54, a price-to-earnings-growth ratio of 0.36 and a beta of 0.55. The company has a quick ratio of 0.97, a current ratio of 2.60 and a debt-to-equity ratio of 1.13.
Hedge Funds Weigh In On Grifols
Several large investors have recently made changes to their positions in the stock. Versant Capital Management Inc acquired a new stake in shares of Grifols in the first quarter valued at $28,000. Tower Research Capital LLC TRC lifted its stake in Grifols by 354.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company's stock worth $60,000 after acquiring an additional 6,335 shares during the last quarter. First Trust Advisors LP purchased a new position in Grifols in the fourth quarter valued at $75,000. Envestnet Portfolio Solutions Inc. purchased a new position in shares of Grifols in the 4th quarter valued at about $77,000. Finally, Ballentine Partners LLC acquired a new stake in shares of Grifols during the 1st quarter worth about $77,000.
About Grifols
(
Get Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
See Also
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
